The Patient Capital Review may be of all-consuming interest to those who work in the tax-advantaged investment sector but, if you are only after a summary of the salient points, Jack Rose is happy to oblige
For those of us who work within the tax-advantaged investment sector, the impending outcome of the Patient Capital Review (PCR) - its possible permutations and consequences - is the talk of the town. ...
Partner Insight: Continuing the Architas education series for clients.
What made financial headlines over the weekend?
290,000 already affected
Putting the tech into protection
Square Mile’s series of informal interviews